FDA decision on BioDelivery's Bunavail expected June 2014
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review BioDelivery Sciences International's new drug application for Bunavail (buprenorphine naloxone buccal film) as a maintenance therapy for opioid dependence, the company revealed on 9 October.